4,2',4',6'-Tetramethoxychalcone

4,2',4',6'-Tetramethoxychalcone

SCHEMBL633892

COc1ccc(/C=C/C(=O)c2c(OC)cc(OC)cc2OC)cc1

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 10/20 0.94
TDP1 Q9NUW8 3/20 0.83
NFKB1 P19838 1/20 0.74
DPP4 P27487 1/20 0.74
NFKB2 Q00653 1/20 0.74
RELA Q04206 1/20 0.74
MAPT P10636 4/20 0.71
TNFRSF1A P19438 2/20 0.71
CYP3A4 P08684 3/20 0.68
KMT2A Q03164 3/20 0.68
TP53 P04637 3/20 0.68
ATM Q13315 1/20 0.68
HSD17B10 Q99714 1/20 0.68
MKNK2 Q9HBH9 1/20 0.67
KDM4E B2RXH2 2/20 0.67
MEN1 O00255 2/20 0.67
HPGD P15428 2/20 0.67
MCL1 Q07820 1/20 0.67
SLC5A1 P13866 1/20 0.67
SLC5A2 P31639 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4,2',4',6'-Tetramethoxychalcone SCHEMBL633215 1.00 ABCG2 (0.94) ABCG2TDP1NFKB1DPP4NFKB2
SCHEMBL10846921 0.92 ABCG2 (0.79) ABCG2TDP1NFKB1DPP4NFKB2
SCHEMBL10846925 0.92 ABCG2 (0.79) ABCG2TDP1NFKB1DPP4NFKB2
Flavokawain A SCHEMBL25209870 0.91 ABCG2 (1.00) ABCG2TDP1NFKB1DPP4NFKB2
Flavokawain A SCHEMBL2289188 0.91 ABCG2 (1.00) ABCG2TDP1NFKB1DPP4NFKB2
Flavokawain A SCHEMBL29349587 0.91 ABCG2 (1.00) ABCG2TDP1NFKB1DPP4NFKB2
Flavokawain A SCHEMBL2289181 0.91 ABCG2 (1.00) ABCG2TDP1NFKB1DPP4NFKB2
SCHEMBL19183198 0.91 ABCG2 (0.88) ABCG2TDP1NFKB1DPP4NFKB2
SCHEMBL19183194 0.91 ABCG2 (0.88) ABCG2TDP1NFKB1DPP4NFKB2
SCHEMBL633184 0.91 NFKB1 (0.89) ABCG2TDP1NFKB1DPP4NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113956226-A Method for synthesizing carvachin 南京科技职业学院 2022-01-21 CN claimed
EP-2810198-B1 ANTI-INVASIVE COMPOUNDS UNIV GENT (BE) 2023-07-12 EP disclosed
US-11342045-B2 Method for determining heterologous biosynthesis pathways KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) 2022-05-24 US disclosed
CN-113956226-A Method for synthesizing carvachin 南京科技职业学院 2022-01-21 CN disclosed
US-20190018922-A1 Method for Determining Heterologous Biosynthesis Pathways KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) 2019-01-17 US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-9290427-B2 Anti-invasive compounds UNIVERSITEIT GENT (BE) 2016-03-22 US disclosed
US-20150011620-A1 ANTI-INVASIVE COMPOUNDS UNIVERSITEIT GENT (BE) 2015-01-08 US disclosed
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1888174-B1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER (US) 2012-02-22 EP disclosed
US-7781410-B2 Compositions containing chalcones and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2010-08-24 US disclosed
US-7781410-B2 Compositions containing chalcones and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2010-08-24 US disclosed
EP-1888174-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS Johnson and Johnson Consumer Companies, Inc. (US) 2008-02-20 EP disclosed
WO-2008019212-A2 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2008-02-14 WO disclosed
US-20080032938-A1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF JOHNSON & JOHNSON CONSUMER INC. 2008-02-07 US disclosed
US-20080032938-A1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF JOHNSON & JOHNSON CONSUMER INC. 2008-02-07 US disclosed
WO-2006127539-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2006-11-30 WO disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045010-A2 STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032938-A1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF CYP17A1, HSD17B7, CUTA ABCG2 937/4885TDP1 4133/4885NFKB1 2286/4885
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 ABCG2 3800/4885TDP1 1761/4885NFKB1 1144/4885
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases APOB, APOL1, HDLBP ABCG2 1177/4885TDP1 813/4885NFKB1 817/4885
US-20150011620-A1 ANTI-INVASIVE COMPOUNDS MMP3, MMP10, MIF ABCG2 216/4885TDP1 3194/4885NFKB1 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.